Myrexis, Inc. (Formerly Known as Myriad Pharmaceuticals, Inc.) Reports Anti-Tumor Activity in a Subset of Patients From Ongoing Phase 2 Azixa(TM) Study in Recurrent Glioblastoma Multiforme at Society for Neuro-Oncology

SALT LAKE CITY, Nov. 19, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced a poster presentation of its lead product candidate Azixa™ (verubulin, MPC-6827) at the 2010 Society for Neuro-Oncology Scientific Meeting and Education Day in Montreal, Canada.